L3VLUP
ProSign in

ZTS · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ZTSLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ZTS
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterZTSLLY
Q3 202027 holders, $13.3bn33 holders, $14.1bn
Q4 202025 holders, $13.7bn29 holders, $17.3bn
Q1 202130 holders, $13.9bn24 holders, $23.0bn
Q2 202128 holders, $15.8bn24 holders, $27.8bn
Q3 202129 holders, $16.6bn31 holders, $29.9bn
Q4 202129 holders, $21.1bn31 holders, $34.7bn
Q1 202236 holders, $17.0bn24 holders, $35.3bn
Q2 202237 holders, $15.4bn33 holders, $42.7bn
Q3 202237 holders, $12.9bn31 holders, $43.4bn
Q4 202230 holders, $12.0bn31 holders, $46.6bn
Q1 202324 holders, $13.3bn33 holders, $44.3bn
Q2 202326 holders, $13.3bn37 holders, $59.6bn
Q3 202323 holders, $13.2bn44 holders, $67.6bn
Q4 202319 holders, $14.5bn45 holders, $73.6bn
Q1 202435 holders, $12.2bn41 holders, $95.3bn
Q2 202424 holders, $10.1bn43 holders, $110bn
Q3 202424 holders, $9.8bn45 holders, $107bn
Q4 202427 holders, $7.7bn46 holders, $93.9bn
Q1 202528 holders, $7.2bn42 holders, $98.4bn
Q2 202526 holders, $6.0bn43 holders, $93.2bn
Q3 202527 holders, $5.9bn39 holders, $86.7bn
Q4 202521 holders, $5.1bn41 holders, $123bn
Q1 202621 holders, $4.4bn39 holders, $106bn
Q2 202623 holders, $2.7bn44 holders, $132bn
ZTS

Zoetis Inc

Holders
21
Reported value
$5.1bn
Buyers
23
Sellers
22

Breadth +1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ZTS (4)

Baillie Gifford & Co, Caxton Associates LLP, MFS Investment Management, Voloridge Investment Management LLC

Only LLY (24)

Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital World Investors, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Marshall Wace LLP, Millennium Management LLC, Moore Capital Management LP, Point72 Asset Management LP, Quantbot Technologies LP, Rokos Capital Management LLP, Steadfast Capital Management LP, T. Rowe Price Associates Inc, Tudor Investment Corp, Walleye Capital LLC, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →